With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

India needs to build a much stronger drug discovery ecosystem to compete globally, says former GSK Pharma MD Annaswamy ...

Britain's life sciences sector plan receives a mixed reception from the pharmaceutical industry. While the strategy aims to boost R&D, industry leaders criticize the lack of resolution on drug pricing ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up ...

Allergy care market grows with rising allergy cases, biologic innovations, and demand for personalized, accessible treatment solutions wor ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which ...

Executives who treat capital allocation as a CEO-level strategic discipline are best positioned to thrive in a volatile and increasingly capital-constrained environment.

As the HR function rapidly evolves to keep pace with a changing world of work, India’s most distinguished people leaders and ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

GSK's business development team have been working overtime of late, with three R&D deals announced in the last few days across Alzheimer's disease and cancer. The Alzheimer's agreement – with ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...